Auna SA (AUNA) 股票分析

公司概述

Auna S.A. operates as a comprehensive healthcare service provider with a footprint spanning Mexico, Peru, and Colombia, delivering essential medical services through its network of hospitals and clinics. The company's business model extends beyond direct patient care to include the provision of prepaid healthcare plans, dental and vision insurance, as well as the distribution of pharmaceutical medicines. Positioned within the Healthcare sector and specifically the Medical Care Facilities industry, the company functions as a critical infrastructure provider for regional health needs. With a market capitalization of $442.60M and annual revenue of $4.39B, Auna S.A. represents a mid-to-large scale entity in the Latin American healthcare landscape. Although specific employee headcount data is not currently disclosed, the revenue magnitude and multi-country operational scope suggest a substantial organizational structure capable of managing complex healthcare logistics. The market capitalization of $442.60M relative to its $4.39B annual revenue indicates that the market values the company at a fraction of its sales, reflecting the capital-intensive nature of operating hospitals and the cyclical or margin-compressed dynamics often present in the medical care facilities industry.

财务健康

The company reported revenue of $4.39B and EBITDA of $819.49M over the trailing twelve months, while net income stood at $97.61M. The significant disparity between the $4.39B revenue and the $97.61M net income reveals a substantial cost structure burden, where operating expenses, including cost of goods sold and administrative costs, consume approximately 97.8% of total revenue. Free cash flow for the period was $47.48M, which provides the company with limited but existing financial flexibility to fund operations or invest in its hospital networks without immediate reliance on external financing. Gross margin sits at 37.9%, indicating the proportion of revenue remaining after direct costs, while the operating margin of 12.8% highlights the efficiency of core business operations before interest and taxes. The profit margin of 2.2% demonstrates the final profitability after all expenses, taxes, and interest, suggesting a highly leveraged or cost-sensitive business model where minor cost increases can significantly impact the bottom line. On the balance sheet, total cash reserves of $365.00M are outweighed by total debt of $3.94B, resulting in a debt-to-equity ratio of 223.10, which characterizes the company as highly leveraged rather than conservative. The current ratio of 1.11 indicates that the company holds slightly more current assets than current liabilities, signaling tight but manageable short-term liquidity conditions that require careful working capital management. Return on Equity stands at 6.5% and Return on Assets is 5.4%, metrics that reveal management effectiveness in generating returns relative to shareholder equity and total asset base, respectively, though these levels are moderate given the company's high leverage.

估值评估

The trailing twelve-month P/E ratio is 15.74, whereas the forward P/E is significantly lower at 5.25. This substantial difference between the current and forward multiples implies that the market expects earnings to grow rapidly in the future to justify the current stock price, or conversely, that current earnings are being suppressed by one-time costs or accounting anomalies. The price-to-book ratio is 0.98, indicating that the market is valuing the company at slightly less than its book value, which suggests the stock trades at a discount relative to the net asset value of its hospitals and clinics. The price-to-sales ratio of 0.10 further underscores the low multiple valuation relative to the massive $4.39B revenue base, while the EV/EBITDA of 5.11 suggests a valuation that is relatively cheap when adjusted for enterprise value and operating cash generation. Regarding trading range, the 52-week high is $7.50 and the 52-week low is $4.46. Without the specific current share price provided in the data, the precise percentage deviation cannot be calculated; however, the stock is trading within a defined volatility band bounded by these extremes. The beta value of 1.64 indicates that the stock exhibits price volatility that is 64% higher than the broader market, making it a more aggressive investment relative to the market average.

Growth & Income

Revenue growth year-over-year is recorded at 6.6%, whereas earnings growth is listed as N/A. The absence of reported earnings growth data prevents a direct comparison of earnings velocity against revenue expansion, but the positive revenue growth suggests an expanding top line that management must eventually translate into bottom-line gains. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all available earnings into growth initiatives, debt reduction, or operational improvements rather than distributing cash to shareholders. This reinvestment strategy is consistent with capital-intensive healthcare operators that prioritize capital allocation toward infrastructure expansion or service line development over income generation. The overall growth and income profile presents a company with solid revenue expansion but no current income distribution, relying entirely on capital appreciation and operational efficiency to deliver value to equity holders.